Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus

doi:10.1084/jem.180.2.595

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Kim, J.
	Articles by Lennon, V.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Kim, J.
	Articles by Lennon, V.


Social Bookmarking

	What's this?

ARTICLES

Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus

J Kim, M Namchuk, T Bugawan, Q Fu, M Jaffe, Y Shi, HJ Aanstoot, CW Turck, H Erlich and V Lennon
Department of Medicine, University of California San Francisco 94143.

The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD65) is a major autoantigen in two human diseases that affect its principal sites of expression. Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of GABA-ergic synaptic transmission in Stiff-Man syndrome (SMS) are both characterized by circulating autoantibodies to GAD65. Anti-GAD65 autoantibodies in IDDM are predominantly directed to conformational epitopes. Here we report the characterization of humoral autoimmune responses to GAD65 in 35 SMS patients, of whom 13 (37%) also had IDDM. All SMS patients immunoprecipitated native GAD65 and the main titers were orders of magnitude higher than in IDDM patients. Furthermore, in contrast to the situation in IDDM, autoantibodies in 35 of 35 (100%) of SMS patients recognized denatured GAD65 on Western blots. Two major patterns of epitope specificity were identified on Western blots. The first pattern, detected in 25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with a linear NH2-terminal epitope residing in the first eight amino acids of GAD65. Nine of nine individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype and HLA-DR3, DQw2 was particularly abundant. The second pattern, detected in 10 of 35 patients (29%) of whom two had IDDM (20%), included reactivity with the NH2-terminal epitope plus strong reactivity with one or more additional epitope(s) residing COOH- terminal to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD65 molecule, but may also include some cases of epitope recognition associated with IDDM resistant HLA- haplotypes. The principal NH2-terminal linear epitope in GAD65 distinguishes the reactivity of SMS and IDDM autoantibodies and may be a determinant of pathogenicity for GABA-ergic neurons. The greater magnitude and distinct specificity of the humoral response to GAD65 in SMS may reflect a biased involvement of the T helper cell type 2 (Th2) subset of CD4+ T cells and antibody responses, whereas IDDM is likely mediated by the Th1 subset of CD4+ T cells and cytotoxic T cell responses.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Saiz, A., Blanco, Y., Sabater, L., Gonzalez, F., Bataller, L., Casamitjana, R., Ramio-Torrenta, L., Graus, F. (2008). Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 0: awn183v1-awn183 [Abstract] [Full Text]
Mayr, A., Schlosser, M., Grober, N., Kenk, H., Ziegler, A. G., Bonifacio, E., Achenbach, P. (2007). GAD Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in Children at Risk for Type 1 Diabetes. Diabetes 56: 1527-1533 [Abstract] [Full Text]
Ronkainen, M. S, Harkonen, T., Perheentupa, J., Knip, M. (2005). Characterization of the humoral immune response to glutamic acid decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and/or type 1 diabetes. Eur J Endocrinol 153: 901-906 [Abstract] [Full Text]
Raju, R., Foote, J., Banga, J. P., Hall, T. R., Padoa, C. J., Dalakas, M. C., Ortqvist, E., Hampe, C. S. (2005). Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients. J. Immunol. 175: 7755-7762 [Abstract] [Full Text]
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J.K., Bingley, P. J., Bonifacio, E., Ziegler, A.-G. (2004). Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics. Diabetes 53: 384-392 [Abstract] [Full Text]
Padoa, C. J., Banga, J. P., Madec, A.-M., Ziegler, M., Schlosser, M., Ortqvist, E., Kockum, I., Palmer, J., Rolandsson, O., Binder, K. A., Foote, J., Luo, D., Hampe, C. S. (2003). Recombinant Fabs of Human Monoclonal Antibodies Specific to the Middle Epitope of GAD65 Inhibit Type 1 Diabetes-Specific GAD65Abs. Diabetes 52: 2689-2695 [Abstract] [Full Text]
Kobayashi, T., Tanaka, S., Okubo, M., Nakanishi, K., Murase, T., Lernmark, A. (2003). Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes. J. Clin. Endocrinol. Metab. 88: 4768-4775 [Abstract] [Full Text]
LOHMANN, T., LONDEI, M., HAWA, M., LESLIE, R. D. G. (2003). Humoral and Cellular Autoimmune Responses in Stiff Person Syndrome. Ann. N. Y. Acad. Sci. 998: 215-222 [Abstract] [Full Text]
Antonini, G, Nemni, R, Giubilei, F, Gragnani, F, Ceschin, V, Morino, S, Bucci, E, Accornero, N (2003). Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus. J. Neurol. Neurosurg. Psychiatry 74: 998-999 [Abstract] [Full Text]
Honnorat, J., Saiz, A., Giometto, B., Vincent, A., Brieva, L., de Andres, C., Maestre, J., Fabien, N., Vighetto, A., Casamitjana, R., Thivolet, C., Tavolato, B., Antoine, J. C., Trouillas, P., Graus, F. (2001). Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies: Study of 14 Patients. Arch Neurol 58: 225-230 [Abstract] [Full Text]
Batstra, M. R., van Driel, A., Petersen, J. S., van Donselaar, C. A., van Tol, M. J., Bruining, G. J., Grobbee, D. E., Dyrberg, T., Aanstoot, H.-J. (1999). Glutamic Acid Decarboxylase Antibodies in Screening for Autoimmune Diabetes: Influence of Comorbidity, Age, and Sex on Specificity and Threshold Values. Clin. Chem. 45: 2269-2272 [Full Text]
Nikoshkov, A., Falorni, A., Lajic, S., Laureti, S., Wedell, A., Lernmark, A., Luthman, H. (1999). A Conformation-Dependent Epitope in Addison's Disease and Other Endocrinological Autoimmune Diseases Maps to a Carboxyl-Terminal Functional Domain of Human Steroid 21-Hydroxylase. J. Immunol. 162: 2422-2426 [Abstract] [Full Text]
Kash, S. F., Johnson, R. S., Tecott, L. H., Noebels, J. L., Mayfield, R. D., Hanahan, D., Baekkeskov, S. (1997). Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid�decarboxylase. Proc. Natl. Acad. Sci. USA 94: 14060-14065 [Abstract] [Full Text]
Tremble, J., Morgenthaler, N. G., Vlug, A., Powers, A. C., Christie, M. R., Scherbaum, W. A., Banga, J. P. (1997). Human B Cells Secreting Immunoglobulin G to Glutamic Acid Decarboxylase-65 from a Nondiabetic Patient with Multiple Autoantibodies and Graves' Disease: A Comparison with Those Present in Type 1 Diabetes. J. Clin. Endocrinol. Metab. 82: 2664-2670 [Abstract] [Full Text]
Namchuk, M., Lindsay, L., Turck, C. W., Kanaani, J., Baekkeskov, S. (1997). Phosphorylation of Serine Residues 3,6,10,and 13Distinguishes Membrane Anchored from Soluble Glutamic Acid Decarboxylase 65and Is Restricted to Glutamic Acid Decarboxylase 65alpha. J. Biol. Chem. 272: 1548-1557 [Abstract] [Full Text]